WorldWide Health News

There maybe hope for men who suffer from Premature Ejaculation, according to pharmaceutical company Johnson and Johnson who are currently seeking approval for their revolutionary drug therapy for this condition. Dapoxetine, originally developed by Eli Lilly and Co, is a short acting SSRI drug which will be entering the final stages of approval later this year. 

Researches at the University of Minnesota, who have lead a trial of the new treatment on 2,600 men effected by Premature Ejaculation, have found that Dapoxetine is capable of increasing the duration of sex for sufferers of the condition by up to three times. News of these findings will be greatly received by the estimated third of the male population effected.

The study, led by Dr Jon Pryor and his team, combined results from two separate trials – one using a 30mg dose of the drug and the other a 60mg dose. At the commencement of the study participants averaged just under a minute before they would ejaculate during sexual intercourse, over the 12 week trial this increased to three minutes and nineteen seconds.

When asked to comment on the conclusions of this study Dr Pryor said “Dapoxetine also improved patients’ perceptions of control over ejaculation, satisfaction with sexual intercourse, and overall impression of change in condition. Partners benefited through improved satisfaction with sexual intercourse.”

A survey recently presented to the American Urology Association, based on data gathered from 1,415 women as part of the Boston Area Community Health survey, has concluded that around 40% of women who have been sexually active with a partner within the last 4 weeks have some degree of Female Sexual Dysfunction, or FSD for short.

The female participants of this study were asked to provide answers to questions relating to their arousal, sexual desire, orgasms, lubrication and if any pain was experienced during sexual intercourse. The findings of this survey concluded that Female Sexual Dysfunction is far more prevalent amongst Caucasian women, with 45% of them showing signs of varying degrees of the condition. The rate amongst Hispanic and African-American women was considerably lower in contrast, with 33% and 31% respectively.

Lead author of the survey, Dr Karen Lutfey of the New England Research Institute, added that although the racial factors where quite significant in her finders there were also many others including age, with women between 60 and 90 being far more likely to report this complaint, as well as those who were married.

Contrary to these high rates of FSD, approximately 40% on average, only 13% of the subjects being dissatisfied with there sex lives and 25% of the women asked being satisfied.